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Myeloperoxidase (MPO) is a biomarker of inﬂammation and oxidative stress
produced by neutrophils, monocytes, and endothelial cells1. MPO levels increase in
patients with heart failure. Increased MPO is associated with prognosis and left
ventricular function in these patients. Heart-type fatty acid-binding protein (H-FABP)
is a low molecular weight (15 kD) cytoplasmic protein, whose role is intracellular
transportation of free fatty acid in the cardiomyocyte.H-FABP is widely used to
evaluate ongoing myocardial damage.
Aim: The aim of the present study was to investigate the relationship between MPO
and myocardial damage.
Methods: We studied 42 consecutive patients with chronic heart failure. Serum
H-FABP and MPO levels were measured by ELISA kits. Routine biochemical and
clinical parameters were recorded. Echocardiographic examinations were performed
in all patients.
Results: Mean age of study groupwas 6712 years. MPO and H-FABP levels were
measured as 255227 (ng/mL) and 60.648.5 (ng/mL) respectively in the study
group. Positive correlation was found between H-FABP and MPO (r¼0.61 p¼0.0001)
(Figure 1). In multiple linear regression analysis, it was found that the age (b¼-0.36,
p¼0.006), creatinine (b¼0.3, p¼0.024) and serum MPO level (b¼0.41, p¼0.009)
were signiﬁcant determinants of H-FABP levels.
Conclusıon: We found that MPO is one of the independent determinants of serum
H-FABP levels. Our results suggest that increased MPO levels may contribute to
ongoing myocardial damage in patients with chronic HF.PP-057
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Aim: Heart failure is a chronic progression characterized by neuroendocrine system
maladaptation. This chronic progressive situation reﬂects an increase in sympathetic
activity and peripheral vascular resistance and a decrease in baroreceptor sensitivity,
and could be the cause of changes in the diurnal rhythm of blood pressure. However,
some trials show that the circadian rhythm of blood pressure in patients with severe
systolic heart failure does not differ from that of control groups. In contrast, trials
generally show that nondipper and reverse dipper patients more frequently experience
severe heart failure. No trials have examined the effects of heart failure etiology for
this situation. Our purpose is to determine the circadian rhythm differences between
ischemic and nonischemic cardiomyopathy patients.
Materıal-Method: Our study included 66 patients: 22 with ischemic cardiomyopathy,
22 with nonischemic cardiomyopathy, and 22 as a control group. The ejection fraction
was under 40% with sinus rhythm, and the left heart was enlarged, with no biven-
tricular pace implantation, no severe heart valve disease; no patient was receiving
dialysis. All patients underwent hemograms and routine laboratory tests and their
BMIs and GFRs were calculated. Echocardiographic tests were conducted on all
patients and each patient took a 24 hour ambulatory blood pressure device and
prepared for the study.C104 JACC VoResults: The ischemic cardiomyopathy group (21M, 1F) had a statistically signiﬁcant
higher male patient ratio than the nonischemic cardiomyopathy group (14M, 8F) and
the control group (13M, 9F). A statistically high statin use also occurred in the
ischemic cardiomyopathy group compared to the nonischemic cardiomyopathy group.
No signiﬁcant differences existed between the ischemic and nonischemic cardiomy-
opathy patients for ejection fraction, age, DM, HT, glomerular ﬁltration rate, body
mass index, hemogram, and routine laboratory tests. In control group dippers, in
nonischemic cardiomyopathy group nondippers, and in ischemic cardiomyopathy
group, the number of reverse dippers was statistically high (p<0.001).
Conclusıon: This study showed that the diurnal rhythm of blood pressure changes in
severe systolic heart failure. In the nonischemic cardiomyopathy group, 54% of the
patients were nondippers and 27.3% were reverse dippers. In the ischemic cardio-
myopathy group, 63.6% of the patients were reverse dippers and 27.3% were non-
dippers. When we combined the ﬁndings of our study, the ischemic cardiomyopathy
group had a higher future mortality and hospitalization than the nonischemic
cardiomyopathy group because the number of reverse dippers was signiﬁcantly higher
in this group. This emphasizes the importance of ambulatory blood pressure moni-
toring and evaluation of the nondipper situation in the prognosis of congestive heart
failure in these patients. Ambulatory blood pressure monitoring has an important role
in determining the drug taking hours.
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Background: The most important adverse event of anthracyclines is cardiotoxicity
and can limit the use of them. Spironolactone is an aldosterone antagonist and has
antiﬁbrotic and antioxidant effects. In the present study, we aimed to investigate
the effects of spironolactone in the prevention of the cardiotoxic effects of the
anthracycline.
Materıals-Methods: A total of 83 female patients who diagnosed with breast cancer
and planned anthracycline including chemotherapy regimen were enrolled in to the
study. Study population were randomized as spironolactone and control group.
Twenty ﬁve mg/day spironolactone was administrated to the patients in spironolactone
group.
Results: LVEF decreased from 67.06.1 to 65.77.4 (p¼0.094) in the spi-
ronolactone group, while from 67.76.3 to 53.66.8 in control group (p<0.001).
Diastolic functional class was prevented in spironolactone group (p¼0.247). In the
control group, however, diastolic functional class was deteriorated (p<0.001). Mitral
inﬂow E wave/lateral wall e’ wave ratio which is one of the most important sign of the
diastolic functions was signiﬁcantly increased in the control group while prevented in
the spironolactone group.
Conclusıons: Prophylactic administration of spironolactone 25 mg/day prevents
the left ventricular systolic and diastolic functions in patients who administrated
anthracyclines.PP-059
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Background: Several cardiac biomarkers including brain natriuretic peptide (BNP)
and NT-pro BNP have been used as predictors of prognosis and negative remodeling
in DCM. In the present study, we aimed to evaluate the prognostic value of Tenascin-
C (TN-C) in dilated cardiomyopathy (DCM). We also aimed to investigate whether
TN-C level can be used to determine reverse remodeling in patient with DCM.l 62/18/Suppl C j October 26–29, 2013 j TSC Abstracts/POSTERS
